A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Former President Biden's prostate cancer diagnosis was revealed in May 2025, four months after he left the White House having decided to drop out of the 2024 presidential race less than a year earlier ...
MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics ...
"Cancer took my dad when he was 56. I was 24 then. I came to believe I would be denied a long life, too. I didn’t admit that to people," columnist Terry Woster writes.
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...
The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and potentially reshape prescribing patterns in oncology and hematology.
With the amazing advances in medicine in the last one hundred years, we are living longer and generally enjoying a higher quality of life as we age. Hip and knee replacements allow us to carry on with ...
Merve Ceylan is a dietitian and health writer with four years of experience writing for companies in the nutrition and health industry. Some foods and drinks can worsen prostate health. Saturated fats ...
Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...
MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces ...
LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results